Phase 1 7 items

Studies

• The first human trial of torcetrapib raises HDL cholesterol by up to 91 percent while producing a lipid profile resembling partial CETP deficiency (Arterioscler Thromb Vasc Biol 2004)Arterioscler Thromb Vasc Biol · January 2004 8
• Phase 1 single ascending dose study of the CETP inhibitor CKD-519 shows potent target inhibition (Drug Des Devel Ther 2016)Drug Des Devel Ther · January 2016 6
• First-in-human data: TA-8995 (obicetrapib) blocks 92-99% of CETP activity and is well tolerated across 1 to 150mg doses (Br J Clin Pharmacol 2014)Br J Clin Pharmacol · September 2014 6
• First-in-human single dose study of the CETP inhibitor BAY 60-5521 shows dose-dependent CETP inhibition and HDL rise (Br J Clin Pharmacol 2012)Br J Clin Pharmacol · February 2012 6
• Doses of dalcetrapib up to 4500 mg, far above the therapeutic dose, are well tolerated in a phase I ascending-dose study (Clin Drug Investig 2011)Clin Drug Investig · January 2011 6
• Multiple-dose study of the CETP inhibitor CP-800,569 shows dose-dependent HDL rise and LDL fall (Clin Pharmacol Ther 2009)Clin Pharmacol Ther · July 2009 6
• Phase 1 trial finds a CETP vaccine induces anti-CETP antibodies and is well tolerated in healthy adults (Atherosclerosis 2003)Atherosclerosis · July 2003 6